StockPreacher.com issues Technical Trading Overview for Advanced Cell Technology Inc.
The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 23, 2009 ) DALLAS, Texas - StockPreacher.com announces an investment report featuring biotechnology company Advanced Cell Technology Inc. (OTCPK: ACTC).
The investment report on Advanced Cell Technology Inc. (OTCPK: ACTC) should be of particular interest to other biotechnology companies: Geron Corp. (Nasdaq: GERN), StemCells Inc. (Nasdaq: STEM) and Aastrom Biosciences Inc. (Nasdaq: ASTM).
The full report is available at: http://www.stockpreacher.com/n/ACTC
Advanced Cell Technology Inc. (ACTC) is a biotechnology company engaged in the development and commercialization of human embryonic and adult stem-cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The Company develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases.
In the report, the analyst notes:
“The hemangioblast (HG) cell program, for which the Company is currently conducting preclinical research programs, investigates the possibility of using stem cells to treat cardiovascular disease, stroke and cancer. The Company has already published positive data in the journal NATURE Methods for its HG cellular program and expects to file the IND over the short term.
“In recent years, ACTC has announced the successful development of a novel technique to generate embryonic stem-cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the Company has announced on multiple occasions the successful creation of human embryonic stem-cell lines without the destruction or disruption of the developmental potential of the embryos. In support of its research and applications ACTC owns or licenses more than 380 patents and patent applications.”
To read the entire report visit: http://www.stockpreacher.com/n/ACTC
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
The investment report on Advanced Cell Technology Inc. (OTCPK: ACTC) should be of particular interest to other biotechnology companies: Geron Corp. (Nasdaq: GERN), StemCells Inc. (Nasdaq: STEM) and Aastrom Biosciences Inc. (Nasdaq: ASTM).
The full report is available at: http://www.stockpreacher.com/n/ACTC
Advanced Cell Technology Inc. (ACTC) is a biotechnology company engaged in the development and commercialization of human embryonic and adult stem-cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The Company develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases.
In the report, the analyst notes:
“The hemangioblast (HG) cell program, for which the Company is currently conducting preclinical research programs, investigates the possibility of using stem cells to treat cardiovascular disease, stroke and cancer. The Company has already published positive data in the journal NATURE Methods for its HG cellular program and expects to file the IND over the short term.
“In recent years, ACTC has announced the successful development of a novel technique to generate embryonic stem-cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the Company has announced on multiple occasions the successful creation of human embryonic stem-cell lines without the destruction or disruption of the developmental potential of the embryos. In support of its research and applications ACTC owns or licenses more than 380 patents and patent applications.”
To read the entire report visit: http://www.stockpreacher.com/n/ACTC
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |